|
1
|
Plunkett W, Huang P, Xu YZ, Heinemann V,
Grunewald R and Gandhi V: Gemcitabine: Metabolism, mechanisms of
action, and self-potentiation. Semin Oncol. 22 4 Suppl 11:S3–S10.
1995.
|
|
2
|
Ahn DH, Krishna K, Blazer M, Reardon J,
Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S and Bekaii-Saab T: A
modified regimen of biweekly gemcitabine and nab-paclitaxel in
patients with metastatic pancreatic cancer is both tolerable and
effective: A retrospective analysis. Ther Adv Med Oncol. 9:75–82.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu Y, Fu JT, Shi D, Feng B and Shi Z:
Clinical efficacy and safety of gemcitabine plus nedaplatin in the
treatment of advanced nasopharyngeal carcinoma. J Cancer Res Ther.
12:C252–C255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan MF, Gottesman S, Boyella R and
Juneman E: Gemcitabine-induced cardiomyopathy: A case report and
review of the literature. J Med Case Rep. 8:2202014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao S, Guo J, Sun L, Lv J and Qiu W:
Gemcitabine-based chemotherapy in colon squamous cell carcinoma: A
case report and literature review. Mol Clin Oncol. 6:561–565.
2017.PubMed/NCBI
|
|
6
|
Lee HS, Park SB, Kim SA, Kwon SK, Cha H,
Lee DY, Ro S, Cho JM and Song SY: A novel HDAC inhibitor, CG200745,
inhibits pancreatic cancer cell growth and overcomes gemcitabine
resistance. Sci Rep. 7:416152017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei MY, Zhuang YF and Wang WM: Gemcitabine
for the treatment of patients with osteosarcoma. Asian Pac J Cancer
Prev. 15:7159–7162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ravikumar B, Sarkar S, Davies JE, Futter
M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M,
Korolchuk VI, Lichtenberg M, Luo S, et al: Regulation of mammalian
autophagy in physiology and pathophysiology. Physiol Rev.
90:1383–1435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choi AM, Ryter SW and Levine B: Autophagy
in human health and disease. N Engl J Med. 368:1845–1846. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim J, Kundu M, Viollet B and Guan KL:
AMPK and mTOR regulate autophagy through direct phosphorylation of
Ulk1. Nat Cell Biol. 13:132–141. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang R, Zeh HJ, Lotze MT and Tang D: The
Beclin 1 network regulates autophagy and apoptosis. Cell Death
Differ. 18:571–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muzes G and Sipos F: Anti-tumor immunity,
autophagy and chemotherapy. World J Gastroenterol. 18:6537–6540.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhong JT, Xu Y, Yi HW, Su J, Yu HM, Xiang
XY, Li XN, Zhang ZC and Sun LK: The BH3 mimetic S1 induces
autophagy through ER stress and disruption of Bcl-2/Beclin 1
interaction in human glioma U251 cells. Cancer Lett. 323:180–187.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
|
16
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Petherick KJ, Williams AC, Lane JD,
Ordonez-Moran P, Huelsken J, Collard TJ, Smartt HJ, Batson J, Malik
K, Paraskeva C and Greenhough A: Autolysosomal β-catenin
degradation regulates Wnt-autophagy-p62 crosstalk. Embo J.
32:1903–1916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sheen JH, Zoncu R, Kim D and Sabatini DM:
Defective regulation of autophagy upon leucine deprivation reveals
a targetable liability of human melanoma cells in vitro and in
vivo. Cancer Cell. 19:613–628. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun T, Li X, Zhang P, Chen WD, Zhang HL,
Li DD, Deng R, Qian XJ, Jiao L, Ji J, et al: Acetylation of Beclin
1 inhibits autophagosome maturation and promotes tumour growth. Nat
Commun. 6:72152015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim G, Kim JY, An HJ, Kang H, Kim TH, Shim
JY, Heo JH, Park HL and Choi YK: The loss of E-cadherin is
associated with the Epigenetic Alteration of CDH1 in breast cancer
and it is also associated with an Abnormal beta-catenin expression
in lobular carcinoma. Korean J Pathol. 43:400–407. 2009. View Article : Google Scholar
|
|
22
|
Luo S and Rubinsztein DC: Apoptosis blocks
Beclin 1-dependent autophagosome synthesis: An effect rescued by
Bcl-xL. Cell Death Differ. 17:268–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by Beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boya P, Gonzaléz-Polo RA, Casares N,
Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D,
Souquere S, Yoshimori T, et al: Inhibition of macroautophagy
triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh
H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al:
Promotion of tumorigenesis by heterozygous disruption of the Beclin
1 autophagy gene. J Clin Invest. 112:1809–1820. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yorimitsu T and Klionsky DJ: Eating the
endoplasmic reticulum: Quality control by autophagy. Trends Cell
Biol. 17:279–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aita VM, Liang XH, Murty VV, Pincus DL, Yu
W, Cayanis E, Kalachikov S, Gilliam TC and Levine B: Cloning and
genomic organization of Beclin 1, a candidate tumor suppressor gene
on chromosome 17q21. Genomics. 59:59–65. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garrington GE, Scofield HH, Cornyn J and
Hooker SP: Osteosarcoma of the jaws. Analysis of 56 cases. Cancer.
20:377–391. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: Where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang C, Li H, Shen C, Lai J, Shi Z, Liu B
and Tao HM: Genistein potentiates the anti-cancer effects of
gemcitabine in human osteosarcoma via the downregulation of Akt and
nuclear factor-κB pathway. Anticancer Agents Med Chem. 12:554–563.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mukubou H, Tsujimura T, Sasaki R and Ku Y:
The role of autophagy in the treatment of pancreatic cancer with
gemcitabine and ionizing radiation. Int J Oncol. 37:821–828.
2010.PubMed/NCBI
|
|
32
|
Teiten MH, Gaascht F, Cronauer M, Henry E,
Dicato M and Diederich M: Anti-proliferative potential of curcumin
in androgen-dependent prostate cancer cells occurs through
modulation of the Wingless signaling pathway. Int J Oncol.
38:603–611. 2011.PubMed/NCBI
|
|
33
|
Hope C, Planutis K, Planutiene M, Moyer
MP, Johal KS, Woo J, Santoso C, Hanson JA and Holcombe RF: Low
concentrations of resveratrol inhibit Wnt signal throughput in
colon-derived cells: Implications for colon cancer prevention. Mol
Nutr Food Res. 52 Suppl 1:S52–S61. 2008.PubMed/NCBI
|
